Insulet Corporation (podd)
PODD — Company Overview
Investors tracking PODD follow a Medical Devices name listed on NMS within Healthcare.
| Ticker | PODD |
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | NMS |
| Market cap | $9.47B |
| Last price | $136.49 |
| Size category | Mid Cap |
PODD — Business Description
The business profile of Insulet Corporation (PODD) reflects its role in Medical Devices. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen fo…
Official website: https://www.insulet.com.
PODD — Investment Thesis
Insulet Corporation (PODD) attracts investors weighing Medical Devices fundamentals against current market pricing.
- Revenue is expanding at roughly 23.5% year-over-year (public data).
- Trailing P/E of 25.61× sits in a moderate band relative to high-growth peers.
- Forward P/E (17.70×) is below trailing P/E — earnings may be expected to improve.
- Equity market capitalization is approximately $9.47B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
PODD — Financial Health
PODD financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin near 12.3% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $236.90M supports balance-sheet flexibility.
| Trailing P/E | 25.61× |
| Forward P/E | 17.70× |
| Price / Sales | 3.10× |
| Price / Book | 6.66× |
| Gross margin | 71.1% |
| Operating margin | 16.2% |
| Profit margin | 12.3% |
| Return on equity | 26.0% |
| Debt / Equity | 66.69 |
| Free cash flow | $236.90M |
PODD — Growth Outlook
Growth outlook for Insulet Corporation (PODD) depends on demand trends in Medical Devices and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 23.5% indicates strong top-line momentum.
- Earnings growth of 3.3% year-over-year supports improving profitability.
- Price is 61.5% below the 52-week high.
- Shares trade 8.0% above the 52-week low — limited rebound so far.
PODD — Competitive Position
Insulet Corporation (PODD) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Medical Devices.
- Market capitalization of $9.47B places PODD among mid-cap peers.
- Gross margin near 71.1% may reflect pricing power or favorable mix.
PODD — Strengths
Strengths for Insulet Corporation (PODD) inferred from public financial metrics:
- Revenue growth of 23.5% year-over-year.
- Earnings growth of 3.3% year-over-year.
- Return on equity near 26.0% — efficient use of shareholder capital.
- Gross margin of 71.1% supports competitive unit economics.
- Positive free cash flow ($236.90M).
- Moderate leverage (debt/equity 66.69).
PODD — Weaknesses
Weaknesses and pressure points for Insulet Corporation (PODD) based on available data:
- Price 62% below the 52-week high — sustained negative sentiment.
PODD — Opportunities
- Sustained revenue growth (23.5%) could support multiple expansion if margins hold.
- Trading 8.0% above the 52-week low — potential recovery if fundamentals stabilize.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
PODD — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
PODD — Summary
Insulet Corporation (PODD) is a mid-cap Healthcare company focused on Medical Devices, listed on NMS. Last price $136.49 with market cap $9.47B. Trailing P/E 25.61×. Revenue grew 23.5% year-over-year per public data. Notable strengths include revenue growth of 23.5% year-over-year. Key watch items include price 62% below the 52-week high — sustained negative sentiment. Review free estimates and earnings pages for PODD; upgrade for institutional ownership and live headlines.
Start Free — open PODD in Vest Terminal
Access live data, filings, ownership, and analysis for Insulet Corporation.
Insulet Corporation FAQ
What does Insulet Corporation (PODD) do?
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes…
What is PODD's P/E ratio?
Insulet Corporation has a trailing P/E of 25.61× based on publicly available market data.
Does PODD pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is PODD in?
Insulet Corporation is classified in Healthcare (Medical Devices) on NMS.
What is PODD's market capitalization?
Approximate market cap: $9.47B.
What are the main risks for PODD?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of PODD?
Potential positives include revenue growth of 23.5% year-over-year, earnings growth of 3.3% year-over-year.
Where can I get analyst estimates for PODD?
Public analyst price targets and consensus for Insulet Corporation are on the free /stocks/podd/estimates page. Deeper estimate history and models are available in Vest Terminal.